Last reviewed · How we verify
Detemir insulin, Aspart insulin, Metformin
This combination therapy uses two insulin types (long-acting detemir and rapid-acting aspart) plus metformin to lower blood glucose by increasing insulin signaling and reducing hepatic glucose production.
This combination therapy uses two insulin types (long-acting detemir and rapid-acting aspart) plus metformin to lower blood glucose by increasing insulin signaling and reducing hepatic glucose production. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (insulin component).
At a glance
| Generic name | Detemir insulin, Aspart insulin, Metformin |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | Insulin combination with biguanide |
| Target | Insulin receptor (detemir and aspart); AMPK and mitochondrial glycerophosphate dehydrogenase (metformin) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Detemir is a basal insulin analog that provides steady, long-acting glucose control by binding to insulin receptors. Aspart is a rapid-acting insulin that covers mealtime glucose spikes. Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity via AMPK activation. Together, they address multiple pathways of hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus (insulin component)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Gastrointestinal disturbance (metformin)
- Lactic acidosis (metformin, rare)
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- MeDiGes Study: Metformine Use in Gestational Diabetes (PHASE3)
- The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study (PHASE4)
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (PHASE3)
- Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (PHASE4)
- Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes (PHASE4)
- Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: